Clinical Trials Logo

Major Depressive Episode clinical trials

View clinical trials related to Major Depressive Episode.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06462820 Not yet recruiting - Clinical trials for Major Depressive Disorder

SAINT for MDD in an Inpatient Setting Follow-on

Start date: June 30, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

Randomized, multi-site, sham-controlled, double-blinded study

NCT ID: NCT06117397 Not yet recruiting - Clinical trials for Major Depressive Episode

A Text Messaging Intervention to Reduce Perinatal Depression Risk

Perinatal TMI
Start date: October 1, 2024
Phase: N/A
Study type: Interventional

Development and preliminary testing of a text messaging intervention that will reduce the risk of a major depressive episode and worsening depressive symptoms in perinatal individuals. The system will screen pregnant individuals, send tailored text messages with links to enhanced content, and will include a peer chat function.This accessible text platform will leverage both the ease of use inherent in text messages and the power of enhanced content drawn evidence from based behavioral interventions (Interpersonal Therapy).

NCT ID: NCT05973643 Not yet recruiting - Clinical trials for Major Depressive Episode

Metabolomics During ElectroConvulsivoTherapy

METECT
Start date: April 30, 2024
Phase: N/A
Study type: Interventional

Investigators will measure the variation of blood Metabolome through 1H NMR at several time points during the course of electroconvulsivetherapy in patients with a major depressive episode. Patients with a major depressive disorder or a bipolar disorder and a current major depressive episode will be included in this study. Investigators hypothesized that Metabolome could be a source to predict response during ECT and to help understanding underlying biological mechanisms.

NCT ID: NCT03693105 Not yet recruiting - Clinical trials for Major Depressive Disorder

The Effects of SAINT® Neuromodulation System on Explicit and Implicit Suicidal Cognition

SAINT®SC
Start date: June 30, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

This multi-site, double-blind, randomized, sham-controlled mechanistic trial aims to test the effects of Magnus Neuromodulation System (MNS) with Stanford Accelerated Intermittent Neuromodulation Therapy (SAINT®) Technology on the neural circuitry of suicidal cognitions in psychiatrically hospitalized patients with Major Depressive Disorder (MDD) and active suicidal ideation (SI). This will be accomplished by applying the MNS with SAINT to a customized target within the left dorsolateral prefrontal cortex (L-DLPFC) identified with fMRI for five consecutive days and measuring resting-state functional connectivity (RS FC) between the subgenual anterior cingulate cortex (sgACC) and the default mode network (DMN) at baseline and immediate-post visit. The relationship between changes in RS FC and changes in both Explicit and Implicit Suicidal Cognitions (ESC and ISC, respectively) will be determined. This study will also determine the relationship between changes in RS FC in neural networks underlying mediators of suicidal cognitions and changes in such mediators with active versus sham SAINT.